Letter: Reactivation Risk Estimates in HBsAg ‐Negative Patients—Definitional, Serological, and Reporting Considerations. Authors' Reply

Kazuya Okushin; Kazuhiko Ikeuchi; Takeya Tsutsumi; Hiroshi Yotsuyanagi

doi:10.1111/apt.71038

Verified record

Letter: Reactivation Risk Estimates in HBsAg ‐Negative Patients—Definitional, Serological, and Reporting Considerations. Authors' Reply

Kazuya Okushin, Kazuhiko Ikeuchi, Takeya Tsutsumi, Hiroshi Yotsuyanagi

Alimentary Pharmacology & Therapeutics2026doi:10.1111/apt.71038

Citation graph

Abstract

No public abstract is available from the verified source records.

Authors

Kazuya Okushin#1 Kazuhiko Ikeuchi#2 Takeya Tsutsumi#3 Hiroshi Yotsuyanagi#4

Institutions

No ROR-resolved institution is linked to this work yet.

Provenance

crossref

Confidence 100%

datacite

Confidence 0%

Referenced works

View all references →

No local reference links have been materialized yet.

Cited by

View all cited-by records →

No local citing links have been materialized yet.

External reference records

10.1111/apt.70992

Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 Update

10.1111/hepr.13504 · 2020

Tenofovir Alafenamide for Prevention of HBV Reactivation in HBsAg‐Negative, Anti–HBc‐Positive Patients Undergoing Rituximab‐Based Chemotherapy: A Multicenter Randomized Controlled Trial

10.1097/hc9.0000000000000859 · 2025

Incidence of Hepatitis B Virus Reactivation in Patients Treated With Immunosuppressive and Chemotherapeutic Agents

10.1111/apt.70749 · 2026

Additional external references

No additional external references are available.